From Surf Wiki (app.surf) — the open knowledge base

Bufexamac

Chemical compound

Field	Value
IUPAC_name	2-(4-butoxyphenyl)-N-hydroxyacetamide
image	Bufexamac Structural Formula V2.svg
image_class	skin-invert-image
Drugs.com
pregnancy_AU
pregnancy_US
legal_AU
legal_CA
legal_UK
legal_US
legal_status	OTC
routes_of_administration	Topical, rectal
excretion	Renal
IUPHAR_ligand	7498
CAS_number	2438-72-4
ATC_prefix	M01
ATC_suffix	AB17
ATC_supplemental
PubChem	2466
ChEMBL	94394
ChemSpiderID	2372
UNII_Ref
UNII	4T3C38J78L
KEGG	D01271
C	12	H=17	N=1	O=3
smiles	ONC(=O)Cc1ccc(OCCCC)cc1
StdInChI	1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
StdInChIKey	MXJWRABVEGLYDG-UHFFFAOYSA-N

| Drugs.com =

| elimination_half-life =

Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe and Australia because of allergic reactions.

Indications

Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns, and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.

Pharmacology

Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce. Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10).

Side effects

Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition. As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.

References

(2020). "Bufexamac Safety advisory - risk of serious skin reactions". Therapeutic Goods Administration.
(2010). "Arzneistoff-Profile". Govi Pharmazeutischer Verlag.
(2000). "Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur". Springer.
(March 2011). "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes". Nature Biotechnology.
(2000). "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt.
(2010-04-22). "European Medicines Agency recommends revocation of marketing authorisations for bufexamac". European Medicines Agency.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

anti-inflammatory-agents hydroxamic-acids phenol-ethers withdrawn-drugs

Want to explore this topic further?

Ask Mako anything about Bufexamac — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report